{"id":"W2792200490","doi":"10.1111/bjd.16426","title":"Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Probity Medical Research; Dalhousie University","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Dosing; Psoriasis; Plaque psoriasis; Adverse effect; Psoriasis Area and Severity Index; Randomized controlled trial; Internal medicine; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004685813,0.0002286869,0.002040096,0.0004381239,0.00007418732,0.00001426927,0.0001783076,0.0003312031,0.00009924249],"category_scores_gemma":[0.0003075194,0.0002100387,0.0001558179,0.0002450371,0.0004147039,0.0001768943,0.00005415109,0.000267815,0.0000030692],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004604924,"about_ca_system_score_gemma":0.0001763421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002958841,"about_ca_topic_score_gemma":0.0002717251,"domain_scores_codex":[0.9968234,0.0009851741,0.001496758,0.0002478194,0.00009000154,0.0003567934],"domain_scores_gemma":[0.9980373,0.0006096142,0.0008930447,0.0001404612,0.0002666685,0.00005288387],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9582141,0.00215794,0.007558254,0.0000259749,0.0007165041,0.0003244096,0.0009558077,0.000008642638,0.0006075268,0.00002907088,0.0002173823,0.02918437],"study_design_scores_gemma":[0.9621144,0.002052218,0.02604732,0.0005477589,0.000300312,0.002815415,0.0001020192,0.000006214805,0.005645894,0.00006124874,0.00009354854,0.0002136797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962781,0.001867933,0.0001781877,0.00006104031,0.0005057416,0.000932735,0.00007533091,0.0000060119,0.0000948965],"genre_scores_gemma":[0.9993114,0.0002820079,0.0002449456,0.00004089622,0.00003388071,0.00001420629,0.00003114591,0.00001924477,0.00002228499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0289707,"threshold_uncertainty_score":0.856513,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008463195056420257,"score_gpt":0.2356017949971449,"score_spread":0.2271385999407246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}